Goodrx is trading 7.3% up at $3.51 after its Q2 earnings report showed stronger-than-expected revenue and an upward revision to its full-year 2026 revenue and Adjusted EBITDA guidance.
- The positive momentum is driven by accelerating Pharma Direct growth, particularly within GLP-1 access programs.
- Management emphasized a strategic shift toward higher-margin manufacturer partnerships and increasing recurring subscription revenue.